title: Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.
abstract: Studies have suggested involvement of interleukin 17 (IL-17) in autoimmune diseases, although its effect on B cell biology has not been clearly established. Here we demonstrate that IL-17 alone or in combination with B cell-activating factor controlled the survival and proliferation of human B cells and their differentiation into immunoglobulin-secreting cells. This effect was mediated mainly through the nuclear factor-kappaB-regulated transcription factor Twist-1. In support of the relevance of our observations and the potential involvement of IL-17 in B cell biology, we found that the serum of patients with systemic lupus erythematosus had higher concentrations of IL-17 than did the serum of healthy people and that IL-17 abundance correlated with the disease severity of systemic lupus erythematosus.
authors.affiliation: Université de Lyon, Institut Fédératif de Recherche 128, Lyon, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Doreau
authors.forename: Alexandre
authors.initials: A
authors.lastname: Belot
authors.forename: Jérémy
authors.initials: J
authors.lastname: Bastid
authors.forename: Benjamin
authors.initials: B
authors.lastname: Riche
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Trescol-Biemont
authors.forename: Bruno
authors.initials: B
authors.lastname: Ranchin
authors.forename: Nicole
authors.initials: N
authors.lastname: Fabien
authors.forename: Pierre
authors.initials: P
authors.lastname: Cochat
authors.forename: Claire
authors.initials: C
authors.lastname: Pouteil-Noble
authors.forename: Pierre
authors.initials: P
authors.lastname: Trolliet
authors.forename: Isabelle
authors.initials: I
authors.lastname: Durieu
authors.forename: Jacques
authors.initials: J
authors.lastname: Tebib
authors.forename: Berhouz
authors.initials: B
authors.lastname: Kassai
authors.forename: Stéphane
authors.initials: S
authors.lastname: Ansieau
authors.forename: Alain
authors.initials: A
authors.lastname: Puisieux
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Eliaou
authors.forename: Nathalie
authors.initials: N
authors.lastname: Bonnefoy-Bérard
mesh_terms: D018941:Antigens, CD19 / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D053264:B-Cell Activating Factor / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007136:Immunoglobulins / Q000378:metabolism; D020381:Interleukin-17 / Q000097:blood* / Q000235:genetics / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000473:pathology; D008297:Male; D015778:Minor Histocompatibility Antigens; D016328:NF-kappa B / Q000378:metabolism; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D051879:Twist-Related Protein 1 / Q000235:genetics / Q000378:metabolism
chemical_list: D018941:Antigens, CD19; D053264:B-Cell Activating Factor; C096816:BCL2-related protein A1; D007136:Immunoglobulins; D020381:Interleukin-17; D015778:Minor Histocompatibility Antigens; D016328:NF-kappa B; D009687:Nuclear Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D012097:Repressor Proteins; C103173:TWIST1 protein, human; C486274:TWIST2 protein, human; D051879:Twist-Related Protein 1